{ Optical Coherence Tomography }

  • The Next Generation of OCT Technology Poised to Take Off and How AI is Reshaping the Future of OCT

    When OCT meets artificial intelligence, a diagnostic revolution quietly arrives:

    Automatic lesion identification: The algorithm based on convolutional neural network (CNN) can complete the pathological analysis of ophthalmic OCT images within 0.3 seconds, identifying dozens of lesions such as macular holes and retinal detachment, with an accuracy rate exceeding 95%

    Real-time surgical navigation: During tumor surgery, the AI-enhanced OCT system can dynamically mark the tumor boundary. Experimental data show that this reduces the residual rate of malignant tissues by 40%

    Elastography breakthrough: The Bayesian neural network strain reconstruction technology developed by the team from Guangdong University of Technology has successfully solved the problem of measuring signals related to chromatographic regression, enabling OCT to map the mechanical properties of tissues and providing a new dimension for the diagnosis of cancer hardness

    Knowledge Corner: The Mystery of “Coherence” in OCT

    Low-coherence interferometry (LCI) is the core technology of OCT. When the light beam reflected from the tissue meets the reference light beam, only the light with an optical path difference less than the coherence length of the light source will interfere. By measuring interference signals, OCT can precisely locate the depth position of scatterers - just like measuring the microscopic world of life with a “ruler” of light.

    oct machine eye

    Full-field OCT (FF-OCT) : Breaking through the traditional resolution limit and achieving cell-level dynamic imaging. In breast cancer surgery, the experimental system has been able to determine within 20 seconds whether there are residual cancer cells at the resection margin

    Chip-level light source: Columbia University has developed a millimeter-level supercontinuum light source chip, replacing traditional bulky lasers and paving the way for handheld OCT devices

    Multimodal fusion: Combining OCT with photoacoustic imaging, fluorescence microscopy and other technologies to simultaneously obtain the triple information of structure, function and molecule. For example, in brain science research, such systems can observe hemodynamics and neuronal activities in parallel



    Despite the bright prospects, OCT still faces practical constraints:

    Penetration depth limitation: The strong scattering characteristics of light in biological tissues limit the effective detection depth to 2-3mm (skin) to 2-3cm (eye).

    Data Ocean Challenge: A single OCT scan of the entire body skin generates data at the GB level, and more intelligent compression analysis algorithms need to be developed

    Standardization dilemma: The differences in equipment parameters among different manufacturers lead to a decline in data comparability, and it is urgent to establish a cross-platform quality control system


    While the latest published papers are still exploring how to optimize the OCT artificial intelligence model, innovators on the clinical front line have begun to rewrite patients' destinies with this technology. From subtle retinal lesions to fatal plaques in coronary arteries, from cancer cells beneath the skin to subtle swells of nerve fibers - this faint light of OCT, which piercings through the fog of life, is quietly reshaping the cognitive boundaries of modern medicine.


    Also welcome to contact us, we are ZD Medical Inc.
    Tel : +86-187 9586 9515
    Email : sales@zd-med.com
    Whatsapp/Mobile : +86-187 9586 9515

  • Holding hands and looking at the eyes to help with diagnosis | Suddenly

    Common causes: tractional retinal detachment (TRD) is mainly caused by the traction of the fibrous vascular membrane on the surface of the retina or within the vitreous. Adult TRD is most commonly seen in proliferative diabetic retinopathy (PDR), retinal vein occlusion (RVO), retinal vasculitis and proliferative vitreoretinopathy (PVR). In addition, trauma, sickle cell retinopathy and uveitis, etc. can also lead to TRD. TRD in children is commonly seen in congenital diseases such as familial exudative vitreoretinopathy (FEVR), retinopathy of prematurity (ROP), and persistent primary vitreous hyperplasia (PHPV).


    Clinical manifestations: The patient's symptoms are closely related to the location and extent of the traction. Typical manifestations include: Decreased vision: Posterior pole detachment can cause a sharp decline in central vision, while early peripheral detachment may be asymptomatic. Visual field defect: Fixed direction black shadow occlusion, a certain area of the visual field: "curtain" -like occlusion. Floaters and flashes of light: When the eyes move, brief "lightning-like" or "fire-like" flashes appear before the eyes, mostly around the visual field. Sudden drop in central vision + distorted vision: This highly indicates macular involvement. If not treated promptly, it may cause irreversible vision damage, such as scar formation and photoreceptor cell necrosis.

    Diagnostic method: Fundus examination: After mydriasis dilation, the indirect ophthalmoscope can reveal the fibrous vascular membrane and its traction on the retina, with or without vitreous hemorrhage. Optical coherence tomography (OCT) : High-resolution display of the morphology of each layer of the retina, assessment of the position of the traction membrane and the involvement of the macular area. B-ultrasound: It is suitable for patients with severe vitreous opacity to assess the degree of traction and the extent of detachment. Fluorescein fundus angiography: It helps identify neovascularization, non-perfusion areas and lesion distribution, which is beneficial for surgical planning.


    Treatment and prognosis: Vitrectomy (PPV) : Removing the proliferative membrane and releasing traction, combined with gas or silicone oil filling to reposition the retina, is the preferred surgical method for TRD. Laser photocoagulation: Targeting ischemic areas or around holes, it reduces new blood vessels and leakage. Anti-vegf drugs: Preoperative injection can reduce the vascular activity of the proliferative membrane and lower the risk of intraoperative bleeding. External scleral compression surgery: It is suitable for peripheral detachment and reduces vitreous traction through external pressure. Postoperative management: Regular follow-up is necessary. Avoid strenuous exercise and intraocular pressure fluctuations. Supplement neurotrophic drugs (such as vitamin B1 and adenosine triphosphate) to promote functional recovery.

    Preventive strategies: Control underlying diseases: For instance, patients with diabetes and hypertension need to strictly manage their blood sugar and blood pressure to delay the progression of retinopathy. Regular ophthalmic screening: High-risk groups (patients with high myopia and diabetes) should have fundus examinations every year. Avoid ocular trauma: Especially for those engaged in high-risk occupations, protective equipment should be worn. Timely treatment of vitreous hemorrhage: Early intervention can reduce the formation of organized membranes.

    The symptoms of tractional retinal detachment are centered around painless visual abnormalities. In the early stage, they may only present as mild floaters or flashes, which are easily overlooked. As the traction intensifies, visual field defects, distorted vision and decreased vision gradually occur. Due to the significant individual differences in symptoms, especially among high-risk groups such as diabetes and high myopia, even if there are no obvious discomforts, regular fundus screening (such as OCT and fundus fluorescein angiography) is still necessary to avoid delaying treatment due to "asymptomatic" conditions. Once the above warning signals occur, it is essential to visit an ophthalmologist as soon as possible and undergo surgery (such as vitrectomy) to relieve the traction and reposition the retina, so as to save vision to the greatest extent.

    Also welcome to contact us, we are ZD Medical Inc.
    Tel : +86-187 9586 9515
    Email : sales@zd-med.com
    Whatsapp/Mobile : +86-187 9586 9515